The Brigham and Women's Hospital, Inc.

The University of North Carolina at Chapel Hill

G1 Therapeutics, Inc.

Benjamin D Humphreys

Jay Copeland Strum

Patrick Joseph Roberts

John Emerson Bisi

Kwok-kin Wong

Norman E Sharpless

Derek P DiRocco

Rafael Kramann

Derek Dirocco

Methods are provided herein for the use of Gli-1 as a specific marker for myofibroblast progenitor cells, thereby permitting the diagnosis of early stages of fibrosis prior to the onset of organ failure. Also provided herein are methods of isolating Gli-1+ cells for e.g., use in high-throughput screening of compounds for the treatment or prevention of fibrosis. In another aspect, provided herein are methods of treating or preventing fibrosis (e.g., kidney fibrosis) in a subject by administering a Gli inhibitor, particularly a Gli-2 inhibitor or a Gli-1/Gli-2 inhibitor.

Uses of GLI1 in detecting tissue fibrosis

The presently disclosed subject matter relates to methods and compositions for protecting cells and or tissues from damage due to ischemia. In particular, the presently disclosed subject matter relates to the protective action of cyclin dependent kinase 4/6 (CDK4/6) inhibitors administered to subjects that have been exposed to, or that are at risk of, ischemia.

Protection of renal tissues from ischemia through inhibition of the proliferative kinases CDK4 and CDK6

Growing community of inventors

Brookline, MA, United States of America

Benjamin D Humphreys